US EditionPublished • loading... • Updated
Ozempic Patent Generation Fight Lobby in Congress - 25/01/2026
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Members associated with bolsonarism at the National Congress are making a change in patent legislation that may delay the arrival of cheaper versions of
Folha de S.PauloReposted by 
UOL
UOLThe closeness of the end of the Brazilian patent of Ozempic, rem gave for diabetes that won the global project because it was used for emagnification, created a dispute between business groups at the National Congress. The current manufacturer defends a bill that may extend its rights to the product in five years, while a national pharmaceutical wants to block the initiative to produce its prias vs. es. Read more (01/25/2026)
·São Paulo, Brazil
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
